Jubilant Pharmova

Quick check

The five things to look at first. Open one for more.

• DebtHigh safetyRated AA+ by 2 agencies.
• ResultsProfit fallingIn the Jun 2026 quarter, sales rose 17% and profit fell 45% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersSteadyThe promoters (founders or parent) own 48% of the company, about the same as in Jun 2025.
• ValuationNormal for this stockThe share trades at 38.8 times its yearly earnings (P/E), pricier than 57% of the time in the last 5 years. Its usual P/E is about 14.

Jubilant Pharmova against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)38.8 against a typical 34.6: pricier than most peers (1st = cheapest).125th of 220
• Sales growth+17.3% against a typical +15.6% from a year earlier.92nd of 197
• Profit growth−45.1% against a typical +18.9% from a year earlier.129th of 160
• Share price, 3 months−3.5% against a typical −0.5%.112th of 200
• Size₹ 14,888.2 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).34th of 199

Exchange filings and their impact on the company.

• 12 Oct 2026Outcome of Board MeetingMedium impactNeutralPrice +2% that day
  Board approved up to Rs 800 cr NCD issue with enabling limit of Rs 2500 cr, raising leverage if fully placed.

  Jubilant Pharmova's board on October 12, 2026 approved issuance of up to 80,000 NCDs of Rs 1 lakh each aggregating up to Rs 800 crore on private placement in one or more tranches, with tenure up to five years. It also decided to seek shareholder approval via postal ballot for an enabling limit of up to Rs 2,500 crore of non-convertible debt outstanding at any time for one year. If fully placed, the Rs 800 crore would materially increase debt but involves no equity dilution.

  Full analysisFiling
• 8 Oct 2026General UpdatesMedium impactPositivePrice −0% on 9 Oct
  Jubilant to invest CAD 94.5m (~Rs 700 cr) to double RUBY-FILL capacity with CAD 23.8m Canada grant.

  Jubilant Draximage will invest CAD 94.5 million (about Rs 700 crore) to modernize and expand its Kirkland, Quebec facility to double production capacity of its flagship cardiac imaging product RUBY-FILL. The Government of Canada will provide CAD 23.8 million in support through the Strategic Response Fund. The company said demand remains very strong with its customer base doubling in the last 3 years, and the expansion will help meet growing global demand.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Hari Shanker Bhartia

Non-Executive Co-Chairman of the Board

Ashish Mukkirwar

Chief Financial Officer

Naresh Kapoor

Compliance Officer, Company Secretary

Arjun Shanker Bhartia

Joint Managing Director, Executive Director

Priyavrat Bhartia

Managing Director, Executive Director